BioStock: SynAct submits IND and recruits first patient

SynAct Pharma is well in line with the communicated plans for the two phase II trials with AP1189 in rheumatoid arthritis – EXPAND and RESOLVE. Most importantly, an IND application has been submitted to the FDA to initiate the RESOLVE study in the US in patients with incomplete response to DMARDs. Another milestone was the enrollment of the first patient in EXPAND, a clinical phase IIb study to investigate the full treatment potential of AP1189 in patients with newly diagnosed rheumatoid arthritis.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/10/synact-submits-ind-and-recruits-first-patient/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se